Evofem Biosciences Inc
OTC:EVFM
Evofem Biosciences Inc
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health. The company is headquartered in San Diego, California and currently employs 119 full-time employees. The company went IPO on 2014-11-20. The company is engaged in developing and commercializing products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). Its product, Phexxi vaginal gel, is a hormone-free, woman-controlled, on-demand prescription contraceptive gel for women. Its lead clinical program is evaluating Phexxi (using the investigational name EVO100) for the prevention of chlamydia and gonorrhea in women. EVO200 vaginal gel (EVO200), its investigational candidate for the reduction of recurrent bacterial vaginosis (BV), uses the same vaginal potential of hydrogen (pH) modulator platform as Phexxi. The company also focuses on developing Multipurpose Prevention Technology (MPT) vaginal gel for indications, including the prevention of human immunodeficiency virus (HIV) in women through Orion Biotechnology Canada Ltd.
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health. The company is headquartered in San Diego, California and currently employs 119 full-time employees. The company went IPO on 2014-11-20. The company is engaged in developing and commercializing products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). Its product, Phexxi vaginal gel, is a hormone-free, woman-controlled, on-demand prescription contraceptive gel for women. Its lead clinical program is evaluating Phexxi (using the investigational name EVO100) for the prevention of chlamydia and gonorrhea in women. EVO200 vaginal gel (EVO200), its investigational candidate for the reduction of recurrent bacterial vaginosis (BV), uses the same vaginal potential of hydrogen (pH) modulator platform as Phexxi. The company also focuses on developing Multipurpose Prevention Technology (MPT) vaginal gel for indications, including the prevention of human immunodeficiency virus (HIV) in women through Orion Biotechnology Canada Ltd.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
